Drug Trial Radar · NCT06910657
IDOV-Immune for Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Jan 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- ViroMissile, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Conditions
- Colorectal Cancer
- Pancreatic Cancer
- Melanoma
- Ovarian Cancer
- Gastric Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
- Breast Cancer
- Sarcoma
- Bladder Cancer
- Lung Cancer
- Prostate Cancer
- Cervical Cancers
- Head and Neck Cancers
- Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)Biological
IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From first dose through the end of the DLT evaluation period (28 days)
- Safety and Tolerability of IDOV-Immune by Dose LevelTime frame: From first dose through end of treatment (28 days) (and/or safety follow-up period as defined in protocol [90 days])
- Determination of the Maximum Tolerated Dose (MTD)Time frame: From first dose through completion of dose-escalation cohorts (2 years)
- Identification of Dose Level(s) for Further Clinical EvaluationTime frame: From first dose through completion of dose-escalation and data review (2 years)
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
South Texas Accelerated Research Therapeutics
San Antonio, Texas · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.